The Long View: When the Drug Escapes the Label

The best long-view stories aren't usually about what happened. They're about what the thing that happened is actually telling you, if you're willing to follow it far enough.

This week, that trail runs from a Phase III obesity readout all the way to the future of genetic medicine.

Pour something. It's a good one.

Chapter 1: The Market That Got Away

Lilly has made a splash once again in the obesity market, with Phase III results for its triple-G agonist retatrutide that raise the bar for obesity drugs. With almost half of patients on the highest dose achieving weight loss of 30% or more, the efficacy is comparable to bariatric surgery. It comes with a higher side effect burden and more discontinuations, including for losing too much weight. Tolerability will provide a boundary on retatrutide's use and on what's achievable for obesity drug development more broadly.

But retatrutide raises a harder question about the limits of this space. Lilly's drug is expected to target patients with higher BMIs who need significant weight loss. That should be a clear segment, but the early experience for the obesity market has shown there are no controls. Traditional payers once set requirements that kept patients on label, but poor coverage pushed them toward compounding and telehealth. The open doors grew the market without restraint. Retatrutide has been a popular black market drug already, with people learning online how to source counterfeit supply.

As much as companies have approached obesity as a medical issue, the public mostly sees it as a lifestyle drug. Physicians are experimenting with dosing frequency, people are micro-dosing or stacking peptides. It would be useful to see trials designed to match real-world use and generate evidence on alternate dosing or side effect mitigation. But manufacturers aren't incentivized to do that.

The coming wave of obesity drugs is focused on beating the early GLP-1s on efficacy or safety, or finding a niche: muscle preservation, long-term maintenance, less frequent dosing. Those are traditional ways to bring more drugs to an established market. But what does it mean if the market isn't behaving like one? More effective drugs carry different risks, but it's hard to envision the public viewing retatrutide as anything other than better weight loss. The payment models and grey-market channels have already created a wild west. Manufacturers will find themselves selling into a market they no longer control.

Chapter 2: Building the Catalog

It's not surprising that big pharma specializes in therapeutic areas where it can leverage its expertise, and so BD activity tends to reflect a trend. Keeping track of those trends, and understanding a company's history, can tell you something about its future.

Lilly just made its fifth genetic medicine acquisition in a year, and that's not an unusual year for it. The Indianapolis company has long been a champion of genetic medicine, making its first major move with the $1bn acquisition of Prevail Therapeutics in December 2020, focused on AAV9-based gene therapies for neurodegenerative diseases. A year later it inked a collaboration with MiNA Therapeutics for five targets worth up to $1.2bn, a deal with ProQR worth up to $1bn for RNA editing across five targets, and launched the Lilly Institute for Genetic Medicine with a $700m facility investment in Boston.

The pace picked up from there: Akouos for $600m in 2022; Sigilon for $35m upfront in 2023; Verve Therapeutics for $1.3bn in June 2025; Adverum for $262m that October; MeiraGTx for up to $475m days later; Orna Therapeutics for $2.4bn in February 2026; and Kelonia Therapeutics, its biggest purchase, for $3.25bn upfront and up to $7bn in April, for a novel lentiviral in vivo CAR-T program with a Phase I lead in multiple myeloma.

That brings us to Engage Biologics, worth up to $202m for a preclinical biotech pioneering non-viral DNA delivery. Engage's Tethosome platform addresses the core limitations of viral vector-based gene therapies: potency, tolerability, and the inability to redose. It combines engineered DNA payloads with lipid nanoparticle delivery and mRNA-encoded Tethosome technology designed to improve localization and expression, while preserving the durability and programmability advantages of DNA-based approaches.

It's not the largest deal on its own. Taken across five years, Lilly has pledged up to $28.3bn and committed at least $5.9bn in cash across eight acquisitions and five partnerships. That tells the story of a company that has decided, with real conviction and real money, to be a leader in genetic medicines.

Chapter 3: The Market That Got Away

A smaller deal with a similarly large picture is Regeneron's collaboration with Parabilis, the latest in a string of partnerships aimed at novel discovery technologies. Regeneron is paying $50m upfront and $75m in equity, with milestones up to $2.2bn, for access to the Helicon peptide platform. Helicons are stabilized, cell-penetrant alpha-helical peptides that engage protein targets inside cells, including flat surfaces that small molecules can't reach. The collaboration covers five initial targets, with options to expand.

The terms sit alongside Regeneron's April deal with Telix for radiopharmaceuticals ($40m upfront, up to $2.1bn in milestones), its $150m upfront acquisition of Tessera's alpha-1 antitrypsin deficiency candidate in December 2025, and its ModeX multispecific antibody collaboration the previous October. Across eleven deals since 2022, Regeneron has committed roughly $930m in confirmed cash against up to $8bn in potential value.

Where Lilly has acquired outright and built infrastructure, Regeneron has favored early-stage partnerships and platform technologies, building off its core VelociSuite antibody capabilities. Both approaches are rational given their balance sheets. Lilly has Zepbound and Mounjaro printing cash. Regeneron is working with a lighter budget and keeping its bets flexible.

The Parabilis deal landed the same week Regeneron disclosed the Phase III failure of its LAG-3 inhibitor fianlimab in metastatic melanoma. The pipeline loss is real. But Regeneron wasn't waiting to find out what it would need. Finding and funding new science is the necessary counterpart to the high-risk stakes of late-stage development.

The timing isn't unfortunate. It's the point.

Obesity drugs that escape their labels. A regulator whose calendar tells you more than his press releases. An ADC field where the easy differentiation is gone and the hard work has started. And two companies quietly building for a future that will not arrive for years, using cash from drugs that are already reshaping how the world thinks about weight.

That is the week. It is also, more or less, the decade.

Taking Monday off as it's a public holiday on both sides of the Atlantic. We'll be back with Trial Tuesday.

Enjoy the long weekend.